A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
This is a phase I, open-label study to assess the safety,tolerability, pharmacokinetics and preliminary efficacy of SH3051 capsule, a small molecule inhibitor of type I transforming growth factor-?(TGF-?) receptor serine/threonine kinase, in patients with advanced solid tumors.
This is a phase I, open-label study to assess the safety,tolerability, pharmacokinetics and preliminary efficacy of SH3051 capsule, a small molecule inhibitor of type I transforming growth factor-?(TGF-?) receptor serine/threonine kinase, in patients with advanced solid tumors.
Tracking Information
- NCT #
- NCT04423380
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jin Li, MD Shanghai East Hospital
Get Well Soon